5U.S.Dept.of Health and Human Services,Food and Drug Administration,Center for Biologics Evaluation and Research.Guidance for industry:use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood components for transfusion to adequately and appropriately reduce the risk of transfusion of HIV-1 and HCV[S].2002-03 (Draft Guidance,HFA-305)http://www.fda.gov/OHRMS/DOCKETS/89fr/02d-qdl001-vol1.pdf.
6Giachetti C,Linnen JM,Kolk DP,et al.Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA[J].J Clin Microbiol,2002,40(7):2408-2419.
7Grant PR,Busch MP.Nucleic acid amplification technology methods used in blood donor screening[J].Transfus Med,2002,12(4):229-242.
8Lelie PN,van Drimmelen HAJ,Cuypers HTM,et al.Sensitivity of HCV RNA and HIV RNA blood screening assays[J].Transfusion,2002,42(5):527-536.
9Candotti D,Richetin A,Cant B,et al.Evaluation of a transcription-mediated amplification-based HCV and HIV-1 RNA duplex assay for screening individual blood donations:a comparison with a minipool testing system[J].Transfusion,2003,43(2):215-225.
10Stramer SL,Glynn SA,Kleinman SH,et al.Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing[J].N Engl J Med,2004,351(8):760-768.
2Brinkmann T,Dreier J,Diekmann J,et al.Alanine aminotransferase cut-off values for blood donor screening using the new International Federation of Clinical Chemistry reference method at 37 degrees C[J].Vox Sang,2003,85(3):159-164.
